PP405 for Androgenetic Alopecia: Mechanism, Studies and Status

A lot of promises, forum rumors and sales offers circulate around PP405. This guide gives the compound a sober assessment: what it is, how it is supposed to work, what the studies actually show, and why you cannot currently buy it from a reputable source. Data as of June 2026.

What is PP405?

PP405 is a small molecule applied topically to the scalp that is designed to reactivate dormant hair follicle stem cells. PP405 is being developed by Pelage Pharmaceuticals, a biotech company spun out of the University of California, Los Angeles (UCLA) in 2018. As of June 2026, the compound is in clinical testing (Phase 2a completed).

Unlike the approved standards, PP405 works neither hormonally (like finasteride) nor by boosting blood flow (like minoxidil). The approach is a completely different one: PP405 intervenes in the energy metabolism of the stem cells and is meant to bring weakened but still present follicles out of the resting phase and back into the growth phase. The exact chemical structure is patented and not publicly known.

The name comes with a little backstory: “Pelage” comes from the French word for fur or coat as a metaphor for hair, and “PP405” combines the company initials with Interstate 405 in Los Angeles (source: Wikipedia, PP405). PP405 is developed specifically for androgenetic alopecia. For scarred scalp or alopecia areata (autoimmune), there is no mechanism of action.

How does PP405 work? (PP405 mechanism)

The way PP405 works rests on a metabolism-based mechanism: PP405 is a dual inhibitor of the mitochondrial pyruvate carrier MPC1 and MPC2. When this carrier is inhibited, pyruvate can no longer enter the mitochondria, builds up inside the cell and is increasingly converted to lactate via lactate dehydrogenase (LDH). This rise in lactate is the actual switch.

Lactate functions in hair follicle stem cells like a biological switch: low lactate levels keep the stem cells in the resting phase (telogen), high levels push them into the growth phase (anagen). A UCLA research team led by Flores et al. demonstrated this principle back in 2017 in the journal Nature Cell Biology (PMID 28812580). It is the scientific basis of PP405.

Specifically, the 2017 study showed: when the enzyme LDHA is switched off in hair follicle stem cells, the follicles stay in telogen and no new hair cycle begins. If, on the other hand, lactate production is increased through an MPC1 deletion, the hair cycle speeds up. PP405 mimics this effect pharmacologically, without touching the hormonal system.

An important point on tolerability: PP405 is formulated to penetrate deep into the scalp but not pass into the bloodstream. In the Phase 1 and Phase 2a data, no PP405 was detectable in blood plasma (source: Pelage Pharmaceuticals, AAD 2024). That points to good local tolerability and against systemic side effects of the kind known, for example, from oral finasteride.

Who is developing PP405? Pelage Pharmaceuticals and the “McLaurin Therapeutics” myth

PP405 is being developed by Pelage Pharmaceuticals, a biotech company spun out of UCLA in 2018 with an exclusive patent and technology license from the university. The scientific core consists of three UCLA researchers: stem cell biologist Dr. William Lowry, metabolism researcher Dr. Heather Christofk, and medicinal chemist Prof. Michael Jung, who synthesized PP405. The company is led by CEO Daniel Gil.

Pelage is solidly funded: in October 2025, the company closed a Series B round of 120 million US dollars, led by ARCH Venture Partners and GV (Google Ventures). That same month, TIME Magazine listed PP405 as one of the “Best Inventions of 2025”. These external signals make PP405 a serious research program, not a garage project.

In search queries and forums, the name “McLaurin Therapeutics” keeps coming up in connection with PP405. There is no verifiable link: neither press releases nor patent databases nor ClinicalTrials.gov name such a company as a developer. All valid sources list exclusively Pelage Pharmaceuticals. “McLaurin Therapeutics” is most likely a mix-up from forum rumors. Be wary of offers that cite company names you cannot verify.

The evidence: what the PP405 studies show (PP405 study)

The PP405 studies have so far run exclusively in the US: Phase 1 (completed January 2024) established safety and the mechanism of action, Phase 2a (results June 2025) provided the first efficacy signals. Before that comes the UCLA basic research from 2017 onward. A Phase 3 PP405 study is announced for 2026 but, as of June 2026, had not yet started.

Phase 1: safety and proof of mechanism

In Phase 1, participants applied a 0.05% PP405 gel for seven days. According to Pelage (presented in the late-breaking session of the 2024 AAD annual meeting), the proliferation marker Ki67 in the hair follicles rose to a statistically significant degree after seven days, measured by scalp biopsy. In addition, new “hair germs” formed, a typical sign of the transition from telogen to anagen. No PP405 was detectable in the blood, and no side effects occurred.

Phase 2a: first efficacy signals

The Phase 2a study (registered as NCT06393452, randomized, double-blind, vehicle-controlled) included 78 participants aged 18 to 55, men with Norwood type III vertex through V and women in Savin classification I-2 through I-4. They applied PP405 0.05% or a placebo vehicle daily for four weeks, with follow-up through week 12.

The central result (source: Pelage Pharmaceuticals, June 2025): among men with a higher degree of loss (Norwood III vertex or higher), 31% of the PP405 group showed more than 20% gain in hair density after 8 weeks, compared to 0% in the placebo group. New terminal hair grew from previously empty follicles, not just fine vellus hair. Here too: no PP405 in the blood, no systemic side effects.

What stands out is the pace: this response appeared after 8 weeks, of which only 4 weeks were active application. Approved treatments like minoxidil and finasteride typically need, according to StatPearls (NCBI), 4 to 6 months before the first visible results. For its assessment, Pelage also introduced the metric “Follicular Unit Count” (the number of active follicular units).

A Phase 2b extension (open-label extension) ran in late 2025 for the former placebo participants; Pelage planned to present full data from it in 2026. At the 2026 AAD annual meeting, Dr. Arash Mostaghimi (Brigham and Women’s Hospital) placed PP405 within an outlook on new hair loss therapies, without citing any new effect figures beyond Phase 2a.

The PP405 study timeline at a glance

PP405 experiences: what study participants report

Real-world PP405 experiences from everyday use do not yet exist, because the compound is not approved and not freely available. The only thing available is the data from the clinical studies (Phase 1 and Phase 2a). Everything else that shows up online as a personal account of “purchased PP405” cannot be verified.

From the studies you can at least draw a realistic picture: local tolerability was good, burning or scalp irritation was not documented in Phase 1 and 2a, and neither were systemic effects. The response was individual: 31% of men with advanced loss responded with more than 20% density gain, the rest fell below that or showed no measurable reaction. Responders and non-responders are the norm in hair therapies.

Be cautious with forum “experiences”: reports about supposedly purchased PP405 (for example on Reddit r/Tressless) most likely refer to JXL069 or similar research chemicals passed off as PP405. Pelage has clarified that JXL069 is not PP405. Such reports therefore say nothing about the real compound.

When will PP405 come to market?

As of June 2026, PP405 is not approved; a market launch is realistic at the earliest between 2027 and 2030 in the US. The Phase 3 study was announced for 2026 but had not yet started. Only after a successful completion can Pelage apply for approval with the US authority, the FDA. All timeframes are estimates, not commitments.

For Germany and the EU it looks even more cautious: an application with the European Medicines Agency (EMA) is not known. After a US approval, an EMA procedure of typically two to three years would be added. Realistically, PP405 is therefore unlikely to be available in Germany before 2030, and presumably it would be prescription-only. A failure in Phase 3 would void the entire timeline.

Can you buy PP405? (buying PP405)

No, you cannot buy PP405. PP405 is not approved and is solely part of clinical studies under the control of Pelage Pharmaceuticals. Anyone searching the internet for “buy PP405” runs into powders, liquids and “research chemicals” sold as PP405. These are not Pelage’s clinical compound, and buying them is risky for several reasons.

The reputable route is through medical advice. Anyone who wants to do something about their hair loss now can turn to the approved options minoxidil and finasteride (with a doctor’s weighing of the risks, see below) or, if follicles are already lost, consider a hair transplant. Waiting for PP405 is one option; self-experimenting with gray-market substances is not.

PP405 vs. minoxidil, finasteride and hair transplant

Compared with minoxidil, finasteride and the hair transplant, PP405 is the only approach not yet approved: a future candidate against three available options. Each method has a different mechanism and a different role. The following matrix sums up the differences, with all values from the sources listed below.

An important safety point on finasteride: in September 2025 (risk information of 16 Sept. 2025), Germany’s BfArM confirmed suicidal thoughts as a side effect; 1 mg packages will in future include a patient information card. Loss of libido and erectile dysfunction are also known. Anyone considering finasteride should weigh this with a doctor. PP405, by contrast, acts locally with no detectable passage into the blood, but has no long-term data yet.

The core message of the table: PP405 is a future hope with interesting first data. Minoxidil and finasteride are available maintenance therapies that work only during use. And the hair transplant is the only method that permanently restores density where follicles are already lost. You can read more about the hereditary form in the article on androgenetic alopecia.

Does PP405 work for women?

The Phase 2a study included men and women (in women, Savin classification I-2 through I-4), but there is so far no robust efficacy data for women. The published results showing more than 20% density gain refer explicitly to men with a higher degree of loss. Pelage has not published separate women’s data from Phase 2a.

This is especially relevant for women, because for female androgenetic alopecia only a single approved treatment exists so far (minoxidil). PP405 could become a second option here, which is a stated research goal of Pelage. That will only become robust, though, with the data from Phase 3, which is set to study men and women in larger numbers. More on this in the article hormones and hair.

The time factor: at which stage can PP405 work?

PP405 can only reactivate follicles that are still present but weakened; follicles that are already permanently lost or scarred cannot be brought back. As long as the stem cells in the so-called bulge region survive, a reactivation is biologically conceivable (basis: Flores et al., Nature Cell Biology 2017). Once they are gone, no compound can replace them.

In practical terms: in early to moderate stages (Norwood I–IV) the follicles are usually only miniaturized and theoretically responsive. With bald areas (Norwood V–VII) the follicles are often gone or the scalp is scarred. Wikipedia (PP405) also points out that PP405 presumably no longer works in advanced, scarred stages. Recognizing it early therefore preserves your options.

What matters is the complementary logic: medication (perhaps PP405 in the future) and hair transplant are not mutually exclusive, they complement each other. In androgenetic alopecia, DHT-sensitive follicles shrink until they disappear. A hair transplant permanently fills already-bald areas with your own, DHT-resistant follicles, while compounds protect and reactivate the surrounding remaining hair.

Conclusion: research with potential, lasting solutions already today

PP405 for androgenetic alopecia is a scientifically grounded, serious research approach built on UCLA basic research (Nature Cell Biology 2017) and first clinical signals from Phase 2a (June 2025). Promising, but still years away from an approval: small sample size, short application, no long-term proof, Phase 3 pending.

Anyone who wants to act now has two sensible routes: in early stages the approved treatments (minoxidil, finasteride with medical counseling), and where follicles are already lost the hair transplant. Both can later be combined with new compounds. Buying supposed PP405 products from the gray market is clearly to be advised against. A free hair analysis clarifies which stage you are in.

Frequently asked questions about PP405 for androgenetic alopecia

Sources